摘要
目的分析不同剂量尿激酶经导管溶栓治疗下肢深静脉血栓形成的疗效。方法回顾分析2018年2月~2019年2月在我院在进行溶栓治疗的120例患者临床资料,依据尿激酶用药剂量、频次分为A(38例)、B(40例)、C(42例)三组。A组12.5万U/次,1次/d;B组12.5万U/次,2次/d;C组25万U/次,2次/d。比较三组治疗后凝血指标[凝血酶原时间(PT)、纤维蛋白原(Fg)、D一二聚体(DD)]、血栓溶解率、术后血栓静脉评分以随访6个月复发率、并发症发生情况。结果治疗后三组PT、Fg、DD比较,差异有统计学意义(P<0.05),且尿激酶用量与凝血指标变化幅度有关(P<0.05);术后三组血栓溶解率随尿激酶用量增加而逐渐升高,血栓静脉评分随尿激酶用量逐渐降低(P<0.05),A组分别与B组、C组比较,差异有统计学意义(P<0.05),B组与C组比较,差异无统计学意义(P>0.05);随访6个月,A、B、C组并发症发生率分别为2.63%、5.00%、7.14%,三组比较差异无统计学意义(P>0.05)。结论不同剂量尿激酶经导管溶栓治疗下肢深静脉血栓疗效存在一定差异,尿激酶每日用量为25 U可实现较高的血栓溶解率和低风险,而增加每日给药频次,可提高血栓溶解率。
Objective To analyze the therapeutic effect of different doses of urokinase through catheter thrombolysis on lower limb deep vein thrombosis.Methods The clinical data of 120 patients undergoing thrombolytic therapy in our hospital from February 2018 to February 2019 were retrospectively analyzed and divided into A(38 cases), B(40 cases), and C( 42 cases) Three groups. Group A: 125,000 U/time, 1 time/d;Group B:125,000 U/time, 2 times/d;Group C: 250,000 U/time, 2 times/d. Compare the coagulation indexes [prothrombin time(PT), fibrinogen(Fg), D-dimer(DD)], thrombolysis rate, postoperative thrombus venous score for 6 months follow-up relapse rate, The occurrence of complications. Results After treatment, the difference of PT, Fg and DD between the three groups was statistically significant( P<0.05), and the amount of urokinase was related to the change range of coagulation index(P <0.05);The rate increased gradually with the increase of urokinase dosage, and the thrombosis vein score gradually decreased with the urokinase dosage, the difference was statistically significant( P<0.05). Group A was compared with groups B and C, the difference was statistically significant(P<0.05),there was no statistically significant difference between group B and group C(P>0.05);after 6 months of follow-up, the incidence of complications in groups A, B, and C were 2.63%, 5.00%, and 7.14%, respectively,there was no statistically significant difference between the three groups(P>0.05).Conclusion There are some differences in the efficacy of different doses of urokinase through catheter thrombolysis for lower limb deep vein thrombosis. The daily dosage of urokinase of 25 U can achieve higher thrombolysis rate and lower risk, while increasing the daily frequency of administration can increase thrombosis dissolution rate.
作者
黄冬琴
吴蔓
HUANG Dong-qin;WU Man(General Surgery,the Second People's Hospital of Yichun City,Yichun 336000,Jiangxi,China)
出处
《医学信息》
2020年第10期122-123,共2页
Journal of Medical Information
关键词
尿激酶
溶栓
下肢深静脉
血栓
Urokinase
Thrombolysis
Deep veins of lower extremities
Thrombosis
